MI-HARMAN
14.9.2022 15:27:35 CEST | Business Wire | Press release
HARMAN International, a wholly-owned subsidiary of Samsung Electronics Co., Ltd. focused on connected technologies and solutions for automotive, consumer and enterprise markets, today announced the introduction of Ready Care — the latest solution in its expanding portfolio of products designed and built to deliver consumer-focused experiences at an automotive grade. Ready Care is a set of solutions — Cognitive Distraction, Stress-Free Routing, and Personalized Comfort — that can work together or independently to improve safety and reduce driver stress.
Ready Care delivers heightened levels of safety and wellbeing through the integration of several key technologies. In addition to employing cameras that can detect driver drowsiness, Ready Care measures real-time driver cognitive load to identify when potential distractions arise, and then offers tailored intervention strategies to maximize safety. The experience is powered by newly developed machine learning algorithms, which gather and process data from in-vehicle cameras and sensors to monitor a driver’s state. Ready Care can then generate customized in-vehicle cabin prompts to trigger a range of behavioral responses — increasing awareness, alleviating stress, or stimulating relief.
“Safety remains a top concern for consumers when considering a new vehicle purchase, and now, with Ready Care, OEMs can improve vehicle safety in a significant new way,” said Armin Prommersberger, Senior Vice President, Automotive Product Management at HARMAN International. “Ready Care is essentially a co-pilot, spotting when distractions could turn into dangerous situations and intervening to avoid them. For the first time, the vehicle can, in a sense, know what the driver is thinking; this is a game changer. We are incredibly proud of and excited by the impact Ready Care will have for drivers, passengers, and everyone on the road.”
Key features of Ready Care include:
- Eyes and Mind on Road: Ready Care measures both driver eye activity and state of mind. An infra-red global shutter camera with active illumination surveys the driver’s face in low and high light environments to provide real-time data into facial expressions, eye gaze, eyelid openings, and more. The HARMAN Cognitive Distraction feature — a real-time driver visual and cognitive load measurement tool — deciphers when the driver is mentally distracted and can initiate multiple and simultaneous in-cabin vehicle intervention responses. It measures real-time driver cognitive load and separates driving tasks from other mental activities as well as visual and manual distractions to enable tailored intervention strategies that maximize safety.
- Stress-free Routing: Compatible with multiple navigation engines, Ready Care provides an alternate route selection to lower elevated driver stress levels while on the road. Through detecting real-time stress factors like traffic jams or weather and adapting accordingly, this solution helps mitigate the driver’s state of stress or anxiety.
- Personalized Experiences: As all journeys and drivers are unique, Ready Care leverages advanced machine learning technology to provide personalized intervention strategies tailored to the individual and their driving experience. Ready Care delivers closed-loop interventions via an SDK, allowing OEMs and third parties to integrate any vehicle feature or function — such as HVAC control, media content and volume, or seat sensors — into the Ready Care solution. An example could be the advanced technologies offered by Gentherm, the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry.
Ready Care equips OEMs with advanced but meaningful technology to improve driver safety and wellbeing. Automotive manufacturers have the opportunity to incorporate the full set of Ready Care solutions into vehicles or choose specific features to create a more customized solution right for their customers and fleets.
For decades, HARMAN has been uniquely positioned at the intersection of automotive and consumer technology innovation, resulting in meaningful, industry-leading solutions. Through its key consumer and technology brands, deep industry expertise, and robust technology stack, HARMAN is equipped to deliver on the promise of consumer experiences through automotive-grade solutions today.
For more information on HARMAN’s Ready Care solution, visit car.harman.com/experiences/ready-care.
About HARMAN
HARMAN (harman.com) designs and engineers connected products and solutions for automakers, consumers, and enterprises worldwide, including connected car systems, audio and visual products, enterprise automation solutions; and services supporting the Internet of Things. With leading brands including AKG®, Harman Kardon®, Infinity®, JBL®, Lexicon®, Mark Levinson® and Revel®, HARMAN is admired by audiophiles, musicians and the entertainment venues where they perform around the world. More than 50 million automobiles on the road today are equipped with HARMAN audio and connected car systems. Our software services power billions of mobile devices and systems that are connected, integrated and secure across all platforms, from work and home to car and mobile. HARMAN has a workforce of approximately 30,000 people across the Americas, Europe, and Asia. In 2017, HARMAN became a wholly-owned subsidiary of Samsung Electronics Co., Ltd.
© 2022 HARMAN International Industries, Incorporated. All rights reserved. Harman Kardon, Infinity, JBL, Lexicon and Mark Levinson are trademarks of HARMAN International Industries, Incorporated, registered in the United States and/or other countries. AKG is a trademark of AKG Acoustics GmbH, registered in the United States and/or other countries. Features, specifications, and appearance are subject to change without notice.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005609/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
